NZ701709A - Monoclonal antibodies to progastrin and their uses - Google Patents

Monoclonal antibodies to progastrin and their uses

Info

Publication number
NZ701709A
NZ701709A NZ701709A NZ70170910A NZ701709A NZ 701709 A NZ701709 A NZ 701709A NZ 701709 A NZ701709 A NZ 701709A NZ 70170910 A NZ70170910 A NZ 70170910A NZ 701709 A NZ701709 A NZ 701709A
Authority
NZ
New Zealand
Prior art keywords
monoclonal antibody
hpg
progastrin
monoclonal antibodies
cell lines
Prior art date
Application number
NZ701709A
Other languages
English (en)
Inventor
Julie Pannequin
Laure Boudier
Frederic Hollande
Dominique Joubert
Original Assignee
Servier Lab
Inst Nat Sante Rech Med
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43086711&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ701709(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab, Inst Nat Sante Rech Med, Centre Nat Rech Scient filed Critical Servier Lab
Publication of NZ701709A publication Critical patent/NZ701709A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G01N33/57535—
    • G01N33/57585—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/595—Gastrins; Cholecystokinins [CCK]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NZ701709A 2009-10-16 2010-10-15 Monoclonal antibodies to progastrin and their uses NZ701709A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25262509P 2009-10-16 2009-10-16
NZ599971A NZ599971A (en) 2009-10-16 2010-10-15 Monoclonal antibodies to progastrin and their uses

Publications (1)

Publication Number Publication Date
NZ701709A true NZ701709A (en) 2016-06-24

Family

ID=43086711

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ701709A NZ701709A (en) 2009-10-16 2010-10-15 Monoclonal antibodies to progastrin and their uses
NZ599971A NZ599971A (en) 2009-10-16 2010-10-15 Monoclonal antibodies to progastrin and their uses

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ599971A NZ599971A (en) 2009-10-16 2010-10-15 Monoclonal antibodies to progastrin and their uses

Country Status (42)

Country Link
US (7) US9611320B2 (enExample)
EP (2) EP3421493B1 (enExample)
JP (3) JP5985987B2 (enExample)
KR (2) KR20120091221A (enExample)
CN (2) CN102791735B (enExample)
AP (1) AP2012006262A0 (enExample)
AR (1) AR078659A1 (enExample)
AU (1) AU2010306119A1 (enExample)
BR (1) BR112012008818B1 (enExample)
CA (1) CA2777691C (enExample)
CL (1) CL2012000914A1 (enExample)
CR (1) CR20120184A (enExample)
CU (1) CU24196B1 (enExample)
CY (1) CY1120913T1 (enExample)
DK (1) DK2488551T3 (enExample)
EA (2) EA029271B1 (enExample)
EC (1) ECSP12011796A (enExample)
ES (2) ES2690943T3 (enExample)
GE (1) GEP201706604B (enExample)
GT (1) GT201200114A (enExample)
HN (1) HN2012000708A (enExample)
HR (1) HRP20181645T1 (enExample)
IL (2) IL219019B (enExample)
IN (1) IN2012DN03348A (enExample)
LT (1) LT2488551T (enExample)
MA (1) MA33747B1 (enExample)
MX (1) MX351635B (enExample)
NI (1) NI201200054A (enExample)
NZ (2) NZ701709A (enExample)
PE (1) PE20121649A1 (enExample)
PH (1) PH12012500711B1 (enExample)
PL (2) PL3421493T3 (enExample)
PT (1) PT2488551T (enExample)
RS (1) RS57966B1 (enExample)
SG (1) SG10201704933PA (enExample)
SI (1) SI2488551T1 (enExample)
SM (1) SMT201800628T1 (enExample)
TN (1) TN2012000159A1 (enExample)
TW (1) TWI537002B (enExample)
UA (1) UA106771C2 (enExample)
WO (1) WO2011045080A2 (enExample)
ZA (1) ZA201202642B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008076454A1 (en) 2006-12-19 2008-06-26 The Board Of Regents Of The University Of Texas System Immunogenic compositions comprising progastrin and uses thereof
US8136651B2 (en) * 2007-12-14 2012-03-20 The Procter & Gamble Company Method and apparatus for orienting articles
PL3421493T3 (pl) * 2009-10-16 2024-04-29 Progastrine Et Cancers S.À R.L. Przeciwciała monoklonalne przeciwko progastrynie i ich zastosowania
US8900588B2 (en) * 2010-01-08 2014-12-02 Les Laboratories Servier Methods for treating breast cancer
US8900817B2 (en) 2010-01-08 2014-12-02 Les Laboratories Servier Progastrin and liver pathologies
US20150071912A1 (en) * 2010-03-24 2015-03-12 Centre National De La Recherche Scientifique (Cnrs) Prophylaxis of colorectal and gastrointestinal cancer
SG187544A1 (en) * 2010-07-26 2013-03-28 Servier Lab Methods and compositions for liver cancer therapy
US8785603B2 (en) * 2011-05-20 2014-07-22 Siemens Healthcare Diagnostics Inc. Antibodies to 25-hydroxyvitamin D2 and D3 and uses thereof
EP2715364A1 (en) 2011-06-01 2014-04-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for predicting the risk of developing a colonic neoplasia
CN105517572B (zh) * 2013-07-05 2019-05-31 华盛顿大学商业中心 用于治疗癌症的中和可溶性mic的单克隆抗体
US10023651B2 (en) 2014-04-18 2018-07-17 The Research Foundation For The State University Of New York Humanized anti-TF-antigen antibodies
ES2843546T3 (es) * 2014-04-18 2021-07-19 The Research Foundation Of The State Univ Of New York Anticuerpos humanizados anti-antígeno-TF
WO2016066671A1 (en) 2014-10-29 2016-05-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating resistant cancers using progastrin inhibitors
WO2017048629A1 (en) * 2015-09-15 2017-03-23 The Scripps Research Institute Antibodies for generating anti-inflammatory macrophage and related uses
PL3397964T3 (pl) * 2015-12-31 2022-02-07 Progastrine Et Cancers S.À R.L. Kompozycje i sposoby do wykrywania i leczenia raka jajnika
MA43550A (fr) * 2015-12-31 2018-11-07 Syncerus S A R L Compositions et procédés d'évaluation du risque d'apparition d'un cancer
ES2899360T3 (es) 2015-12-31 2022-03-11 Progastrine Et Cancers S A R L Composiciones y procedimientos para detectar y tratar cáncer gástrico
AU2018246368B2 (en) * 2017-03-30 2023-02-09 Ecs-Progastrin Sa Compositions and methods for detecting lung cancer
KR102317805B1 (ko) * 2017-03-30 2021-10-27 이씨에스-프로가스트린 에스에이 전립선암을 검출하기 위한 조성물 및 방법
PL3720879T3 (pl) * 2017-12-05 2022-09-12 Progastrine Et Cancers S.À R.L. Terapia skojarzona przeciwciałami przeciwko progastynie i immunoterapią w leczeniu nowotworu
CN112004560A (zh) 2017-12-08 2020-11-27 Ecs生物识别系统有限公司 癌症诊断中的放射性标记的前胃液素
TW201940881A (zh) 2018-01-26 2019-10-16 瑞士商Ｅｃｓ前胃泌激素公司 在癌症診斷中結合前胃泌激素檢測與其他癌症生物標記的技術
KR102699073B1 (ko) * 2018-02-27 2024-08-26 이씨에스-프로가스트린 에스에이 면역치료요법용 생체표지자로서 프로가스트린
TWI793238B (zh) * 2018-12-27 2023-02-21 偉喬生醫股份有限公司 體外檢測生物樣品之胃源性蛋白的方法及套組
US20220372125A1 (en) * 2019-10-02 2022-11-24 Aslan Pharmaceuticals Pte. Ltd. Antigen Specific Binding Domains and Antibody Molecules
CN112062846A (zh) * 2020-04-27 2020-12-11 杭州博茵生物技术有限公司 一种g-17单克隆抗体及其应用
CN115785273B (zh) * 2021-09-10 2023-10-31 东莞市朋志生物科技有限公司 一种抗胃蛋白酶原i的抗体及其应用
CN115724949A (zh) * 2022-12-12 2023-03-03 郑州伊美诺生物技术有限公司 一种鼠源lgG单克隆抗体及其制备方法、应用
CN116143920A (zh) * 2022-12-30 2023-05-23 南京岚煜生物科技有限公司 胃泌素17的单克隆抗体及其细胞株的制备方法和应用
EP4509528A1 (en) * 2023-08-16 2025-02-19 Barrelman Biosciences LLC Monoclonal antibodies against veterinary progastrin-like molecules and their uses
CN117567611B (zh) * 2023-11-22 2024-05-14 艾维可生物科技有限公司 抗成熟型胃泌素17的单克隆抗体及其应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DK0710719T3 (da) 1990-01-12 2007-07-09 Amgen Fremont Inc Frembringelse af xenogene antistoffer
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
EP1794586B1 (en) * 2004-09-22 2013-01-30 Cancer Advances, Inc., Monoclonal antibodies to progastrin
ES2727306T3 (es) * 2006-05-22 2019-10-15 Inst Nat Sante Rech Med Inhibidores de progastrina en el tratamiento del cáncer de colon
WO2008076454A1 (en) 2006-12-19 2008-06-26 The Board Of Regents Of The University Of Texas System Immunogenic compositions comprising progastrin and uses thereof
US20110318380A1 (en) * 2008-10-01 2011-12-29 Dako Denmark A/S MHC Multimers in Cancer Vaccines and Immune Monitoring
PL3421493T3 (pl) * 2009-10-16 2024-04-29 Progastrine Et Cancers S.À R.L. Przeciwciała monoklonalne przeciwko progastrynie i ich zastosowania
US20150071912A1 (en) * 2010-03-24 2015-03-12 Centre National De La Recherche Scientifique (Cnrs) Prophylaxis of colorectal and gastrointestinal cancer
SG187544A1 (en) * 2010-07-26 2013-03-28 Servier Lab Methods and compositions for liver cancer therapy

Also Published As

Publication number Publication date
CY1120913T1 (el) 2019-12-11
US20170174761A1 (en) 2017-06-22
CA2777691C (en) 2018-02-27
PH12012500711B1 (en) 2019-04-24
PE20121649A1 (es) 2012-12-08
US9611320B2 (en) 2017-04-04
JP2013507138A (ja) 2013-03-04
TN2012000159A1 (en) 2013-12-12
CA2777691A1 (en) 2011-04-21
ES2973217T3 (es) 2024-06-19
US20170306011A1 (en) 2017-10-26
IL219019B (en) 2019-05-30
GT201200114A (es) 2014-08-11
KR101640520B1 (ko) 2016-07-19
CR20120184A (es) 2012-08-20
AU2010306119A1 (en) 2012-05-03
US11299542B2 (en) 2022-04-12
SI2488551T1 (sl) 2019-01-31
JP2017212992A (ja) 2017-12-07
IN2012DN03348A (enExample) 2015-10-23
KR20120091221A (ko) 2012-08-17
LT2488551T (lt) 2018-10-25
MX351635B (es) 2017-10-23
PH12012500711A1 (en) 2012-11-12
TWI537002B (zh) 2016-06-11
BR112012008818B1 (pt) 2021-10-19
DK2488551T3 (en) 2018-10-08
US20220195035A1 (en) 2022-06-23
CN102791735A (zh) 2012-11-21
IL254004A0 (en) 2017-10-31
EP2488551A2 (en) 2012-08-22
IL219019A0 (en) 2012-06-28
US20180022802A1 (en) 2018-01-25
RS57966B1 (sr) 2019-01-31
GEP201706604B (en) 2017-01-25
WO2011045080A3 (en) 2011-07-07
TW201119675A (en) 2011-06-16
CU20120060A7 (es) 2013-04-19
EA029271B1 (ru) 2018-03-30
US20110117086A1 (en) 2011-05-19
JP2015145380A (ja) 2015-08-13
PT2488551T (pt) 2018-10-31
CL2012000914A1 (es) 2012-09-14
US10385126B2 (en) 2019-08-20
MX2012004400A (es) 2012-06-27
JP5985987B2 (ja) 2016-09-06
AR078659A1 (es) 2011-11-23
CN102791735B (zh) 2016-05-18
JP6272793B2 (ja) 2018-01-31
EP3421493B1 (en) 2024-01-17
EP3421493C0 (en) 2024-01-17
HN2012000708A (es) 2015-06-22
ZA201202642B (en) 2013-06-26
IL254004B2 (en) 2023-06-01
ECSP12011796A (es) 2012-06-29
HRP20181645T1 (hr) 2018-12-14
US10385125B2 (en) 2019-08-20
WO2011045080A2 (en) 2011-04-21
EP3421493A1 (en) 2019-01-02
SMT201800628T1 (it) 2019-01-11
CU24196B1 (es) 2016-09-30
PL3421493T3 (pl) 2024-04-29
HK1178183A1 (zh) 2013-09-06
ES2690943T3 (es) 2018-11-23
NZ599971A (en) 2014-12-24
SG10201704933PA (en) 2017-07-28
EA201200597A1 (ru) 2012-12-28
AP2012006262A0 (en) 2012-06-30
MA33747B1 (fr) 2012-11-01
US10385124B2 (en) 2019-08-20
US20170306012A1 (en) 2017-10-26
EP2488551B1 (en) 2018-07-25
US20200002413A1 (en) 2020-01-02
PL2488551T3 (pl) 2019-01-31
KR20150082672A (ko) 2015-07-15
UA106771C2 (uk) 2014-10-10
NI201200054A (es) 2012-08-20
BR112012008818A2 (en) 2018-05-22
CN104628857A (zh) 2015-05-20
EA201791876A1 (ru) 2018-01-31
US10377821B2 (en) 2019-08-13

Similar Documents

Publication Publication Date Title
NZ701709A (en) Monoclonal antibodies to progastrin and their uses
NZ604003A (en) Monoclonal antibodies against her2
MY150984A (en) Anti-agf antibodies
NZ607680A (en) Novel antigen binding proteins
MX2018013008A (es) Anticuerpos st-2 humanos solubles y ensayos.
MX353476B (es) Anticuerpos anti-cxcl13 y metodos para usarlos.
MX354143B (es) Minicuerpos j591 y diacuerpos-cys para apuntar con especificidad de objetivo a un antígeno de membrana específico para próstata de humano (psma) y métodos para su uso.
MX2019015352A (es) Linfocitos t con receptor de antigeno quimerico (car) para receptor 1 huerfano tipo receptor de tirosina cinasa (ror 1).
TN2014000120A1 (en) Cd27l antigen binding proteins
JO3538B1 (ar) الاجسام المضادة المتفاعلة مع b7-h3 والاجزاء النشطة مناعياً المتعلقة بها واستخداماتها
UA107574C2 (ru) Гуманизированное антитело, специфическое к протофибрилярной формы бета-амилоидного пептида
PH12012502022B1 (en) Anti-erbb3 antibodies
NZ628314A (en) Cd47 antibodies and methods of use thereof
NZ601588A (en) Methods for treating breast cancer
MY150400A (en) Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof
NZ626610A (en) Antibodies that bind csf1r
MX2010002406A (es) Terapia de combinacion con anticuerpos anti-cd20 de tipo i y de tipo ii.
BR112012010698A2 (pt) método para tratamento de um sujeito com câncer, método de triagem de uma célula de câncer de mama, e , anticorpo
EP2566890A4 (en) ANTI-PAI-1 ANTIBODIES AND METHOD FOR THEIR USE
PE20120902A1 (es) Anticuerpos anti-egfl7 humanizados
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
NZ594682A (en) Fully human antibodies specific to cadm1
MX347247B (es) Agentes capaces de la activación de células t regulatorias cd4+cd25+ y su uso en el tratamiento de enfermedad.
NZ607472A (en) Treatment for neoplastic diseases
PH12013500432A1 (en) Anti-vegfr-3 antibody compositions

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 15 OCT 2017 BY AJ PARK

Effective date: 20161221

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 OCT 2018 BY AJ PARK

Effective date: 20171003

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 OCT 2019 BY ACUMASS

Effective date: 20180918

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 OCT 2020 BY ACUMASS

Effective date: 20190917

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 OCT 2021 BY ACUMASS

Effective date: 20201013

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 OCT 2022 BY ACUMASS

Effective date: 20211013

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 OCT 2023 BY ACUMASS

Effective date: 20221004

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 OCT 2024 BY ACUMASS

Effective date: 20230920

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 OCT 2025 BY ACUMASS

Effective date: 20241004

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 OCT 2026 BY ACUMASS

Effective date: 20250919